Outlook Therapeutics Inc (NASDAQ:OTLK) shares, rose in value on Thursday, April 16, with the stock price up by 5.84% to the previous day’s close as strong demand from buyers drove the stock to $1.45.
Actively observing the price movement in the last trading, the stock closed the session at $1.37, falling within a range of $1.36 and $1.49. The value of beta (5-year monthly) was 0.472. Referring to stock’s 52-week performance, its high was $9.29, and the low was $0.87. On the whole, OTLK has fluctuated by -1.36% over the past month.
With the market capitalization of Outlook Therapeutics Inc currently standing at about $47.30 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-13.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 702.6k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that OTLK’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of OTLK currently trading nearly 10.54% and -1.15% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 55.82, while the 7-day volatility ratio is showing 11.08% which for the 30-day chart, stands at 10.95%. Furthermore, Outlook Therapeutics Inc (OTLK)’s beta value is 0.36, and its average true range (ATR) is 0.13.
A comparison of Outlook Therapeutics Inc (OTLK) with its peers suggests the former has fared considerably weaker in the market. OTLK showed an intraday change of 5.84% in last session, and over the past year, it shrunk by -83.43%%.
Data on historical trading for Outlook Therapeutics Inc (NASDAQ:OTLK) indicates that the trading volumes over the past 10 days have averaged 0.42 and over the past 3 months, they’ve averaged 534.47K. According to company’s latest data on outstanding shares, there are 24.91 million shares outstanding.
Nearly 37.11% of Outlook Therapeutics Inc’s shares belong to company insiders and institutional investors own 16.25% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.75 million shares as on 2025-03-31, resulting in a short ratio of 8.71. According to the data, the short interest in Outlook Therapeutics Inc (OTLK) stood at 1515.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 3.5 million. The stock has fallen by -23.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the OTLK stock heading into the next quarter.
